# Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

> **NCT04222413** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 116 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Metastatic Pancreatic Cancer
- Pediatric Solid Tumor
- Advanced Breast Cancer
- Malignant Peripheral Nerve Sheath Tumor
- Colorectal Neoplasms

## Interventions

- **DRUG:** Metarrestin

## Key facts

- **NCT ID:** NCT04222413
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-27
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04222413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04222413, "Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04222413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*